1例局部进展期直肠癌新辅助治疗后病理完全缓解的治疗并文献复习
Treatment of a Case of Locally Advanced Rectal Cancer in Pathological Complete Response after Neoadjuvant Therapy and Literature Review
DOI: 10.12677/acm.2024.1492479, PDF,   
作者: 体澳铧:西安医学院研究生院,陕西 西安;陕西省人民医院普外科,陕西 西安
关键词: 直肠肿瘤新辅助放化疗病理完全缓解Rectal Neoplasms Neoadjuvant Chemoradiotherapy Pathological Complete Respond
摘要: 目前最新数据显示结直肠癌在全球发病率与死亡率分别位居第3位和第2位,术前新辅助治疗联合全直肠系膜切除(total mesorectal excision, TME)已成为进展期直肠癌的标准化治疗方案。局部进展期直肠癌(LARC)患者目前术前新辅助治疗后获得病理完全缓解(pCR)较为少见,但通常生存预后更好。本文报告了一例LARC患者成功接受了新辅助治疗方案,接受了保留肛门这一重要器官的根治性手术,并获得令人满意的pCR结果。在回肠造口还纳术后16个月内明显改善了生活质量,后续的复查中并未出现复发。我们希望通过该病例报告对之后的LARC患者的治疗提供参考,当然,对该患者的长期随访以及未来大型的临床循证研究才是评估该方案有效性的理论支持。
Abstract: The recent available data show that colorectal cancer (CRC) as the third most diagnosed cancer and the second leading cause of cancer death globally, and preoperative neoadjuvant therapy combined with total mesorectal excision (TME) has become a standardized treatment option for progressive rectal cancer. Patients with locally advanced rectal cancer (LARC) currently achieve pathological complete response (pCR) after preoperative neoadjuvant therapy more rarely, but usually have a better survival prognosis. In this paper, we report a case of a patient with LARC who successfully underwent a neoadjuvant treatment regimen, underwent radical surgery with preservation of the anus, a vital organ, and achieved a satisfactory pCR. The quality of life improved significantly within 16 months after ileostomy reduction, and there was no recurrence on subsequent review. We hope that this case report will provide a reference for the treatment of subsequent patients with LARC, and of course, the long-term follow-up of this patient and future large-scale clinical evidence-based studies will be the theoretical support for evaluating the effectiveness of this program.
文章引用:体澳铧. 1例局部进展期直肠癌新辅助治疗后病理完全缓解的治疗并文献复习[J]. 临床医学进展, 2024, 14(9): 428-435. https://doi.org/10.12677/acm.2024.1492479

参考文献

[1] (2024) Global Cancer Burden Growing, Amidst Mounting Need for Services. Saudi Medical Journal, 45, 326-327.
[2] 杨鋆, 辛城霖, 张忠涛. 中低位直肠癌的精准诊断与规范治疗[J]. 中华消化外科杂志, 2024, 23(1): 85-90.
[3] 黎健霞, 邓艳红, 汪建平. 直肠癌新辅助治疗方案选择: 单纯化疗或同步放化疗[J]. 中华胃肠外科杂志, 2018, 21(6): 627-631.
[4] Benson, A.B., Venook, A.P., Al-Hawary, M.M., Azad, N., Chen, Y., Ciombor, K.K., et al. (2022) Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 1139-1167. [Google Scholar] [CrossRef] [PubMed]
[5] Serra-Aracil, X., Pericay, C., Badia-Closa, J., Golda, T., Biondo, S., Hernández, P., et al. (2023) Short-term Outcomes of Chemoradiotherapy and Local Excision versus Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: A Multicentre Randomised, Controlled, Phase III Trial (the TAU-TEM Study). Annals of Oncology, 34, 78-90. [Google Scholar] [CrossRef] [PubMed]
[6] Maas, M., Nelemans, P.J., Valentini, V., Das, P., Rödel, C., Kuo, L., et al. (2010) Long-Term Outcome in Patients with a Pathological Complete Response after Chemoradiation for Rectal Cancer: A Pooled Analysis of Individual Patient Data. The Lancet Oncology, 11, 835-844. [Google Scholar] [CrossRef] [PubMed]
[7] 郭兰伟, 张兴龙, 蔡林, 等. 全球结直肠癌流行和防控现状[J]. 中华肿瘤杂志, 2024, 46(1): 57-65.
[8] 中华人民共和国国家卫生健康委员会, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2023年版) [J]. 中华外科杂志, 2023, 61(8): 617-644.
[9] 彭俊杰, 朱骥, 刘方奇, 等. 中国局部进展期直肠癌诊疗专家共识[J]. 中国癌症杂志, 2017, 27(1): 41-80.
[10] 刘骞, 王锡山. 筋膜导向在低位直肠癌侧方淋巴结清扫中的应用价值[J]. 中华胃肠外科杂志, 2019, 22(5): 432-435.
[11] 中华医学会外科学分会疝与腹壁外科学组, 中华医学会外科学分会结直肠外科学组, 中国医师协会外科医师分会疝和腹壁外科专家工作组, 等. 结直肠癌腹壁侵犯转移外科诊治中国专家共识(2024版) [J]. 中国实用外科杂志, 2024, 44(6): 601-609.
[12] 李绍堂. 直肠癌侧方淋巴结清扫的关键问题探讨[J]. 中华结直肠疾病电子杂志, 2023, 12(3): 190-195.
[13] 孙跃明. 中低位直肠癌主淋巴结转移和清扫的争议与探讨[J]. 中华消化外科杂志, 2022, 21(6): 743-748.
[14] Biniaz, M., Moradi, A., Basit, M.G., Pashaki, A.S., Dehghan, A. and Mohammadian, K. (2024) Combination of Neoadjuvant and Adjuvant Chemotherapy with FOLFOX Compared with Adjuvant Chemotherapy in Management of Locally Advanced Rectal Cancers: A Randomized Trial of a Promising Therapeutic Approach. BMC Cancer, 24, Article No. 863. [Google Scholar] [CrossRef] [PubMed]
[15] Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., et al. (2004) Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. New England Journal of Medicine, 351, 1731-1740. [Google Scholar] [CrossRef] [PubMed]
[16] Huang, C., Huang, M., Ma, C., Yeh, Y.S., Tsai, H., Huang, C., et al. (2017) Neoadjuvant FOLFOX Chemotherapy Combined with Radiotherapy Followed by Radical Resection in Patients with Locally Advanced Colon Cancer. Radiation Oncology, 12, Article No. 48. [Google Scholar] [CrossRef] [PubMed]
[17] Akgun, E., Ozkok, S., Tekin, M., Yoldas, T., Caliskan, C., Kose, T., et al. (2017) The Effects of Chemoradiotherapy on Recurrence and Survival in Locally Advanced Rectal Cancers with Curative Total Mesorectal Excision: A Prospective, Nonrandomized Study. World Journal of Surgical Oncology, 15, Article No. 205. [Google Scholar] [CrossRef] [PubMed]
[18] van Gijn, W., Marijnen, C.A., Nagtegaal, I.D., Kranenbarg, E.M., Putter, H., Wiggers, T., et al. (2011) Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-Up of the Multicentre, Randomised Controlled TME Trial. The Lancet Oncology, 12, 575-582. [Google Scholar] [CrossRef] [PubMed]
[19] Maas, M., Beets-Tan, R.G.H., Lambregts, D.M.J., Lammering, G., Nelemans, P.J., Engelen, S.M.E., et al. (2011) Wait-and-see Policy for Clinical Complete Responders after Chemoradiation for Rectal Cancer. Journal of Clinical Oncology, 29, 4633-4640. [Google Scholar] [CrossRef] [PubMed]
[20] Smith, J.J., Strombom, P., Chow, O.S., Roxburgh, C.S., Lynn, P., Eaton, A., et al. (2019) Assessment of a Watch-And-Wait Strategy for Rectal Cancer in Patients with a Complete Response After Neoadjuvant Therapy. JAMA Oncology, 5, e185896. [Google Scholar] [CrossRef] [PubMed]
[21] Dossa, F., Chesney, T.R., Acuna, S.A. and Baxter, N.N. (2017) A Watch-And-Wait Approach for Locally Advanced Rectal Cancer after a Clinical Complete Response Following Neoadjuvant Chemoradiation: A Systematic Review and Meta-analysis. The Lancet Gastroenterology & Hepatology, 2, 501-513. [Google Scholar] [CrossRef] [PubMed]
[22] López-Campos, F., Martín-Martín, M., Fornell-Pérez, R., García-Pérez, J.C., Die-Trill, J., Fuentes-Mateos, R., et al. (2020) Watch and Wait Approach in Rectal Cancer: Current Controversies and Future Directions. World Journal of Gastroenterology, 26, 4218-4239. [Google Scholar] [CrossRef] [PubMed]
[23] Ogura, A., Konishi, T., Cunningham, C., Garcia-Aguilar, J., Iversen, H., Toda, S., et al. (2019) Neoadjuvant (Chemo)Radiotherapy with Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients with Low CT3/4 Rectal Cancer. Journal of Clinical Oncology, 37, 33-43. [Google Scholar] [CrossRef] [PubMed]
[24] Peeters, K.C.M.J., Marijnen, C.A.M., Nagtegaal, I.D., Kranenbarg, E.K., Putter, H., Wiggers, T., et al. (2007) The TME Trial after a Median Follow-Up of 6 Years: Increased Local Control but No Survival Benefit in Irradiated Patients with Resectable Rectal Carcinoma. Annals of Surgery, 246, 693-701. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, S., Jiang, T., Xiao, L., Yang, S., Liu, Q., Gao, Y., et al. (2021) Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. The Oncologist, 26, e1555-e1566. [Google Scholar] [CrossRef] [PubMed]
[26] Bahadoer, R.R., Dijkstra, E.A., van Etten, B., Marijnen, C.A.M., Putter, H., Kranenbarg, E.M., et al. (2021) Short-course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 29-42. [Google Scholar] [CrossRef] [PubMed]
[27] Garcia-Aguilar, J., Patil, S., Gollub, M.J., Kim, J.K., Yuval, J.B., Thompson, H.M., et al. (2022) Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. Journal of Clinical Oncology, 40, 2546-2556. [Google Scholar] [CrossRef] [PubMed]
[28] Conroy, T., Bosset, J., Etienne, P., Rio, E., François, É., Mesgouez-Nebout, N., et al. (2021) Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 702-715. [Google Scholar] [CrossRef] [PubMed]
[29] 欧阳淦露, 孟文建, 舒佩, 等. 全程新辅助治疗在高危局部晚期直肠癌患者中的疗效和安全性分析[J]. 中华胃肠外科杂志, 2019(4): 349-356.
[30] Donnelly, M., Ryan, O.K., Ryan, É.J., Creavin, B., O’Reilly, M., McDermott, R., et al. (2023) Total Neoadjuvant Therapy versus Standard Neoadjuvant Treatment Strategies for the Management of Locally Advanced Rectal Cancer: Network Meta-Analysis of Randomized Clinical Trials. British Journal of Surgery, 110, 1316-1330. [Google Scholar] [CrossRef] [PubMed]
[31] 陈功, 张荣欣, 伍小军, 等. 局部进展期直肠癌放化疗后病理完全缓解患者的临床研究[J]. 中华胃肠外科杂志, 2016, 19(6): 664-667.
[32] Wei, M.Y., Cao, K., Hong, W., Yeung, J., Lee, M., Gibbs, P., et al. (2024) Artificial Intelligence Measured 3d Body Composition to Predict Pathological Response in Rectal Cancer Patients. ANZ Journal of Surgery, 94, 1286-1291. [Google Scholar] [CrossRef] [PubMed]
[33] Mehraj, A., Baba, A., Khan, B., Khan, M., Wani, R., Parray, F., et al. (2022) Predictors of Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. Journal of Cancer Research and Therapeutics, 18, 391. [Google Scholar] [CrossRef] [PubMed]
[34] Grabenbauer, A., Aigner, T., Göbel, H., Leibl, B.J., Lamberti, C., Grabenbauer, G.G., et al. (2023) Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under “Real World“ Conditions? Cells, 12, Article 399. [Google Scholar] [CrossRef] [PubMed]
[35] Armstrong, D., Raissouni, S., Price Hiller, J., Mercer, J., Powell, E., MacLean, A., et al. (2015) Predictors of Pathologic Complete Response after Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. Clinical Colorectal Cancer, 14, 291-295. [Google Scholar] [CrossRef] [PubMed]
[36] Zhang, Q., Liang, J., Chen, J., Mei, S. and Wang, Z. (2021) Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. Asian Pacific Journal of Cancer Prevention, 22, 1607-1611. [Google Scholar] [CrossRef] [PubMed]
[37] Cheng, Y., Qin, Q., Huang, X., Lan, P., Wang, L., Gao, X., et al. (2019) Effect of Interval between Preoperative Radiotherapy and Surgery on Clinical Outcome and Radiation Proctitis in Rectal Cancer from FOWARC Trial. Cancer Medicine, 9, 912-919. [Google Scholar] [CrossRef] [PubMed]
[38] 中国医师协会外科医师分会结直肠外科医师专业委员会, 中华医学会外科学分会结直肠外科学组, 国家卫生健康委员会能力建设和继续教育外科学专家委员会结直肠外科专业委员会, 等. 结直肠系膜、筋膜和间隙的定义及名称中国专家共识(2023版) [J]. 中华胃肠外科杂志, 2023, 26(6): 529-535.
[39] 秦启元, 吴雅丽, 蔡永华, 等. 直肠癌新辅助放化疗前切除术后近远期吻合口漏的临床特征及预后因素分析[J]. 中华胃肠外科杂志, 2021, 24(6): 513-522.
[40] 吴迪, 王楠, 吴涛, 等. 低位直肠癌前切除术后预防性回肠造口方式对转流性结肠炎发病及转归的影响[J]. 中华结直肠疾病电子杂志, 2021, 10(1): 61-69.
[41] 陶俊, 束宽山, 郑明, 等. 回肠双腔造口对中低位直肠癌前切除术后转流性结肠炎的发生及疾病转归的影响[J]. 中国老年学杂志, 2023, 43(19): 4655-4658.